Publications by authors named "A B Galway"
Article Synopsis
- Biliary tract cancers show strong resistance to treatments, and effective therapies for these advanced cases are currently limited.
- A clinical trial combined DKN-01 and nivolumab to see if they could help patients with advanced biliary tract cancer, but no positive results were found.
- Researchers analyzed tissue samples to identify different cell types that contribute to the cancer's resistance, discovering new immune and malignant cell states that could inform future treatment strategies.
Background: CheckMate 040 assessed the efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is needed to support the management of treatment-related adverse events (TRAEs). This analysis assessed the safety of nivolumab monotherapy in the phase I/II, open-label CheckMate 040 study.
View Article and Find Full Text PDFUroliths (urinary stones) are routinely found in both domestic and exotic animals kept under human care. In zoos, Asian small-clawed otters (ASCOs, Aonyx cinereus) have been identified as being particularly prone to this disease. Risk factors are thought to be nutritional; however, recommendations contradict each other, depending on which physiological model was used.
View Article and Find Full Text PDFPurpose: Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS) of 10.
View Article and Find Full Text PDF